HealthSTAT News
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Join the argument
House rules →Comments load as you scroll.